This content is in French.
Enzalutamide in mHSPC: Equal efficacy and tolerance after 75 years of age?
10 novembre 2025
By Lila Rouland | Published on November 10, 2025 | 4 min readMetastatic hormone-sensitive prostate cancer (mHSPC) represents a major therapeutic challenge, particularly in older patients who are frequently underrepresented in clinical trials due to comorbidities, physiological frailty, or concerns about increased adverse effects. Yet, over 65% of prostate cancer–related deaths occur in men aged 75
By Lila Rouland | Published on November 10, 2025 | 4 min read
Metastatic hormone-sensitive prostate cancer (mHSPC) represents a major therapeutic challenge, particularly in older patients who are frequently underrepresented in clinical trials due to comorbidities, physiological frailty, or concerns about increased adverse effects. Yet, over 65% of prostate cancer–related deaths occur in men aged 75 years or older, highlighting the need to adapt treatment strategies for this population. The ARCHES study, already known for demonstrating the benefit of enzalutamide combined with androgen deprivation therapy (ADT), presents here a post hoc analysis comparing outcomes in patients younger than 75 versus those aged 75 and older, to determine whether age influences efficacy, safety, and quality of life.
Metastatic hormone-sensitive prostate cancer (mHSPC) represents a major therapeutic challenge, particularly in older patients who are frequently underrepresented in clinical trials due to comorbidities, physiological frailty, or concerns about increased adverse effects. Yet, over 65% of prostate cancer–related deaths occur in men aged 75 years or older, highlighting the need to adapt treatment strategies for this population. The ARCHES study, already known for demonstrating the benefit of enzalutamide combined with androgen deprivation therapy (ADT), presents here a post hoc analysis comparing outcomes in patients younger than 75 versus those aged 75 and older, to determine whether age influences efficacy, safety, and quality of life.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Saad, F., et al. (2023). Clinical outcomes of enzalutamide in metastatic hormone-sensitive prostate cancer in patients aged <75 and ≥75 years […]. The Lancet Healthy Longevity, 4(10), e656–e667.
View the source
